EO 14273
Lowering Drug Prices by Once Again Putting Americans First
HealthcareEconomy & Trade
Ad Space (leaderboard)
Summary
This executive order directs the Secretary of Health and Human Services to improve the Medicare Drug Price Negotiation Program by enhancing transparency and minimizing impacts on pharmaceutical innovation, while also seeking to reduce Medicare Part D premiums and align treatment of different drug types to address what the order characterizes as distortions in the current program.
Key Points
- 1HHS Secretary must propose guidance within 60 days for the Medicare Drug Price Negotiation Program, prioritizing high-cost drugs and minimizing negative impacts on pharmaceutical innovation
- 2Administration officials have 180 days to recommend ways to stabilize and reduce Medicare Part D premiums
- 3HHS Secretary directed to work with Congress to align treatment of small molecule drugs with biological products in the negotiation program
- 4Order criticizes the Biden Administration's approach to drug pricing and references reversing previous policies from the first Trump administration
- 5Secretary authorized to develop and test alternative payment models for high-cost drugs for seniors within one year
This summary is for informational purposes only. It may not capture all nuances of the executive order. Always refer to the official text for authoritative information.
Ad Space (rectangle)